Introduction {#s1}
============

Evoking potent and tailored antiviral responses by the host is paramount in combating viral infections ([@B1]). Dendritic cells (DCs) induce antiviral immune responses by recognizing invading viruses via pattern recognition receptors (PRRs). PRR triggering by viral pathogen-associated molecular patterns (PAMPs) induces DC maturation and activation as well as differentiation of naïve T cells ([@B2]--[@B4]). Certain PRRs such as the RIG-I-like receptors (RLRs) induce strong antiviral innate immune responses initiated by expression of type I interferon (IFN) responses. RLRs are cytosolic PRRs and sense virus infection by detection of specific viral RNA structures ([@B5], [@B6]). RIG-I (DDX58) and MDA5 are two well-described RLRs and important in antiviral immunity to e.g., Influenza viruses, Dengue virus, and West Nile virus ([@B7]--[@B9]). RIG-I recognizes both uncapped 5′ppp single stranded (ss) RNA and short double stranded (ds) RNA, whereas MDA5 senses long dsRNA ([@B7], [@B10], [@B11]). Upon activation, RIG-I and MDA5 engage with mitochondrial antiviral protein MAVS, leading to MAVS multimerization and subsequent recruitment of adaptor molecule TRAF3. TRAF3 mediates recruitment of serine/threonine-protein TANK-binding kinase 1 (TBK1) and IκB kinase ε (IKKε), resulting in activation of transcription factors IRF3 and NF-κB, leading to type I IFN and cytokine transcription ([@B12], [@B13]). Autocrine and paracrine ligation of IFNβ to the heterodimeric transmembrane IFN receptor (IFNAR) on the cell surface ultimately results in transcription of a broad spectrum of interferon-stimulated genes (ISGs), of which many exhibit strong antiviral activity ([@B14]--[@B18]). NF-κB activation regulates transcriptional activation of a plethora of cytokine genes, including IL-1β and TNF that are important in innate immunity ([@B19]). In addition, IFNβ is crucial in driving IL-27 synthesis and thereby CD8^+^ T cell-dependent adaptive immune responses ([@B20]). Moreover, both IRF3 and NF-κB are involved in the induction of cytokines important in T helper (T~H~) 1 differentiation ([@B21]--[@B23]).

Recently, the cytosolic DEAD-box RNA helicase 3 (DDX3) that resembles cytosolic DEAD box helicase RIG-I and MDA5, was shown to function as a PRR for human immunodeficiency virus 1 (HIV-1) ([@B24]--[@B27]). DDX3 acts as a host factor for various viruses including hepatitis B and C virus and West Nile virus, facilitating virus replication ([@B8], [@B28], [@B29]). Thus, DDX3 is an important host factor for viruses and its function as a PRR might prevent escape of viruses from DDX3.

DDX3 is a well-known host factor required for HIV-1 propagation due to its role in transport of viral *Tat* mRNA and subsequent formation of translation initiation complexes ([@B30]--[@B32]). Upon initiation of HIV-1 infection, deficient transcription elongation leads to formation of prematurely aborted RNAs ([@B33], [@B34]). Interestingly, DDX3 senses these abortive HIV-1 RNA transcripts, leading to MAVS-dependent type I IFN responses, indicating that DDX3 is a viral PRR for HIV-1 ([@B27]).

Abortive HIV-1 RNAs are generated during the early steps of HIV-1 transcription, consisting of an HIV-1-specific complex secondary RNA hairpin-like structure (TAR loop) and a 5′cap, but lacking a poly A tail ([@B33], [@B34]). The complex structure of the TAR loop, together with the 5′cap is required for binding to DDX3, while the absence of the poly A tail prevents engagement of DDX3 with the cellular translational machinery ([@B30]). Gringhuis et al. have shown that DDX3 is an important PRR that senses abortive HIV-1 RNA transcripts upon HIV-1 infection. However, during infection of DCs, HIV-1 hijacks DC-SIGN function to block MAVS signaling, thereby preventing type I IFN and cytokine responses, and subsequently preventing the induction of antiviral innate and adaptive immune responses ([@B27], [@B35]). Due to this viral inhibition mechanism, the breadth and potency of abortive HIV-1 RNAs in inducing antiviral immunity remains elusive.

To characterize the role of abortive HIV-1 RNA in establishing innate and adaptive immune responses without interference due to DC-SIGN inhibition, we developed a synthetic 5′capped HIV-1 RNA of 58 nucleotides that mimics the naturally occurring abortive HIV-1 RNA (HIV-1 Cap-RNA~58~). Our data strongly suggest that HIV-1 Cap-RNA~58~ induces potent type I IFN responses in monocyte-derived DCs, macrophages as well as primary CD1c^+^ DCs. Furthermore, HIV-1 Cap-RNA~58~ is a potent stimulus that induces both innate and adaptive immune responses in monocyte-derived DCs. HIV-1 Cap-RNA~58~-dependent induction of DC maturation and cytokine secretion leads to T~H~2 differentiation. Notably, HIV-1 Cap-RNA~58~ responses inhibited ongoing HIV-1 infection. Our data further define the importance of sensing abortive HIV-1 transcripts to evoke strong antiviral immunity and provide a rationale for using HIV-1 Cap-RNA~58~ in vaccine design strategies.

Materials and Methods {#s2}
=====================

RNA Constructs
--------------

The synthetic abortive HIV-1 RNAs were designed based on the HIV-1 genome. HIV-1 Cap-RNA~58~ consists of nucleotides 1--58 from the HIV-1 genome, including a 5′m^7^GTP cap but lacking the poly A tail. HIV-1 Cap-RNA~630~ consists of nucleotides 1--630 and also contains the 5′m^7^GTP cap and is lacking the poly A tail. The 5′m^7^GTP cap was incorporated using co-capping of 5′m^7^GTP during *in vitro* transcription (IVT) (Biosynthesis, [Table S1](#SM4){ref-type="supplementary-material"}) as previously described ([@B27]). As a control RNA, 1--58 nucleotides were synthesized lacking the 5′cap (HIV-1 control RNA~58~). HIV-1 Cap-RNA~58~ and HIV-1 control RNA~58~ structures were predicted with the MFOLD program.

Myeloid Cell Stimulations
-------------------------

This study was performed according to the Amsterdam University Medical Centers, location AMC Medical Ethics Committee guidelines and all donors gave written informed consent in accordance with the Declaration of Helsinki. CD14^+^ monocyte isolation and subsequent generation of monocyte-derived DCs was performed as previously described ([@B36]). CD14^+^ monocytes were cultured in IMDM supplemented with 10% FCS, 10 U/mL penicillin and 10 mg/mL streptomycin (IMDM complete, Invitrogen) O/N at 37°C 5% CO~2~ for monocyte stimulations or cultured for 6 days in IMDM complete supplemented with GM-CSF (800 U/mL, Invitrogen) to obtain monocyte-derived macrophages. Stimulations were performed on day 1 (monocytes) or day 6 (monocyte-derived macrophages and DCs). CD1c^+^ DCs were isolated using human CD1c^+^ dendritic cell isolation kit (Miltenyi Biotec) according to manufacturer\'s instructions. Cells were stimulated with synthetic HIV-1 RNAs (1 nM, Biosynthesis) complexed with transfection reagent lyovec (InvivoGen), polyinosinic:polycytidylic acid complexed with lyovec (poly-I:C, 4 μg/mL, InvivoGen) and lipopolysaccharide (LPS) *Salmonella enterica* serotype typhimurium (10 ng/mL, Sigma). Poly-I:C concentration series were performed with molecular weight ranges from 223801.1 to 895204.4 g/mol. Cells were pre-incubated with blocking IFNα/βR antibodies (clone MMHAR2, 20 μg/mL) and BAY 11--7082 (2 μM) for 30 min and 2 h, respectively.

RNA Interference
----------------

RNA interference was performed using the Neon Transfection System according to manufacturer\'s protocol (Thermo Fisher). On day 4 of monocyte-derived DC cultures, cells were washed with PBS, resuspended in buffer R (Thermo Fisher) and divided according to the different short interfering (si) SMARTpool RNAs (all from Dharmacon). siDDX3 (M-006874-01), siMAVS (M-024237-02) or siNon-Target as a control (D-001206-13) were added to DC-buffer R mixtures and transfection of DCs with the siRNAs was achieved by subjecting them to 1,500V for 20 ms. Transfected cells were seeded in 24-wells plates in RPMI 1640 with 10% FCS (Invitrogen) and 2 mM L-glutamine (Lonza), without antibiotics. After 48 h, viable cells were harvested, washed and seeded in a 96-wells round bottom plate and incubated overnight at 37°C, 5% CO~2~. Seventy-two hours after transfection, silencing of expression of target proteins in DCs was confirmed by quantitative real-time PCR and flow cytometry ([Figure S1](#SM1){ref-type="supplementary-material"}) and cells were stimulated as previously described.

Quantitative Real-Time PCR
--------------------------

mRNA was extracted using an mRNA capture kit (Roche) and was reverse transcribed to cDNA using a reverse transcriptase kit (Promega). Quantitative real-time PCR was performed on an ABI 7500 Fast Real-Time PCR detection system (Applied Biosystems) using SYBR Green (Thermo Fisher), with primers that were designed using Primer Express 2.0 (Applied Biosystems, [Table S2](#SM5){ref-type="supplementary-material"}). Expression of genes of interest were normalized to expression of household gene *GAPDH*, according to the formula Nt = 2^Ct(GAPDH)−Ct(target)^. For each donor, expression levels induced upon stimulation with HIV-1 Cap-RNA~58~ were set as 1.

Flow Cytometry
--------------

DCs were stimulated for 24 or 48 h, fixed with 4% paraformaldehyde (pFA) and stained with PE-conjugated anti-CD80 (1:12.5, 557227, BD pharmingen), allophycocyanin-conjugated CD83 (1:25, 551073, BD Pharmingen), FITC-conjugated anti-CD86 (1:25, 555657, BD Pharmingen), PE-conjugated anti-HLA-DR (1:25, 555812, BD Pharmingen), or PE-Cy7-conjugated anti-CD40 (1:100, 2165055, Sony Biotechnology). Expression levels after RNA interference were determined using anti-DDX3 or anti-MAVS (1:50, 2635S or 3993S, Cell Signaling) followed by PE-conjugated donkey anti-rabbit (1:200, Jackson Immuno Research). HIV-1 infection levels were assessed using anti-p24 (1:200, KC57-RD1, Beckman Coulter). Flow cytometric analysis was performed using the FACSCanto II (BD Biosciences) and FlowJo software v10.

p65 and IRF3 Translocation
--------------------------

DCs were stimulated for 4 h, fixed with 4% pFA and permeabilized with 0.2% Triton X-100 in PBS. p65 was stained with anti-p65 (1:50, 8242S, Cell Signaling) and IRF3 with anti-IRF3 (1:50, 4302S, Cell Signaling), followed by a secondary donkey anti-rabbit labeled with Alexa-546 (1:400, Invitrogen) and 1 μg/mL Hoechst (Invitrogen) and cellular localization was visualized with a 100x magnification, using Leica DM6 B upright microscope. Analysis was performed with LAS X Navigator software. Nuclear extracts (NE) were prepared 4 h after DC stimulation, using the NucBuster protein extraction kit (Novagen). Twenty micrograms of NE per sample was used to detect nuclear p65 or IRF3 using the TransAM NF-κB-p65 and IRF3 kits (Active Motif). OD450 nm values were measured using BioTek Synergy HT.

Elisa
-----

DC supernatants were harvest 24 or 48 h after stimulation and secretion of TNF, IL-6, and IL-12p70 protein (eBiosciences) was measured by ELISA as described by manufacturer. OD450 nm values were measured using BioTek Synergy HT.

T Cell Proliferation and Differentiation
----------------------------------------

To assess T cell proliferation levels, DCs were primed with stimuli and cocultured in a 1:4 ratio with allogeneic peripheral blood lymphocytes (PBLs) isolated from buffy coats of healthy donors (Sanquin) labeled with CellTrace Violet (Thermo Fisher). On day 3, IL-2 was added (10 U/mL, Chiron). After 5 days, cells were fixed with 4% pFA and stained with FITC-conjugated anti-CD3 (1:100, 11003642, ebioscience), PerCP-Cy5.5-conjugated anti-CD4 (1:20, 332772, BD Biosciences), PE-Cy7-conjugated anti-CD8 (1:100, 25008742, eBioscience) and fixable viability dye eFluor780 (1:4000, 65-0865-14, ebioscience). Proliferation was assessed in viable CD4^+^ and CD8^+^, CD3^+^ T cells. To examine T~H~ cell differentiation, DCs were primed for 48 h with stimuli or LPS (10 ng/mL) in combination with IFNγ (1,000 U/mL, u-CyTech) or PGE~2~ (1 μM, Sigma), as positive controls for T~H~ 1 and 2 skewing, respectively. DCs were cocultured in the presence of *Staphylococcus aureus* enterotoxin B (10 pg/mL, Sigma) in a 1:4 ratio with allogeneic naïve T cells that were isolated from PBMCs or PBLs from buffy coats with a human CD4^+^ T cell isolation kit II (Miltenyi Biotec), with PE-conjugated anti-CD45RO (Dako) and anti-PE beads (Miltenyi Biotec) according to manufacturer\'s instructions. On day 5, IL-2 was added (10 U/mL, Chiron). After 11--13 days, resting T cells were restimulated with PMA (10 ng/mL, Sigma) and ionomycin (1 mg/mL, Sigma) for 6 h and treated with brefeldin A (10 μg/mL, Sigma) for the final 4 h. Cells were fixed for flow cytometry analysis with 4% pFA, permeabilized using 0.1% saponin in PBS and stained with FITC-conjugated anti-IFNγ (1:5, 340449, BD Biosciences) and allophycocyanin-conjugated anti-IL-4 (1:25, 554486, BD Biosciences) to determine T~H~ 1 and 2 differentiation, respectively. Cells were analyzed using the FACS Canto II (BD Biosciences) and FlowJo software v10.

Virus and Infection
-------------------

DCs were infected with R5 HIV-1 strain NL4.3 BaL. NL4.3 BaL was produced as described previously ([@B34], [@B37]). For DC infection, a multiplicity of infection (MOI) of 0.1--0.2 was used, depending on the virus batch. DCs were infected for 24 h, washed extensively and left in the presence of HIV-1 control RNA or HIV-1 Cap-RNA~58~ for 5 days, after which intracellular p24 levels were measured using flow cytometry to determine infection.

Statistical Analysis
--------------------

Statistics were performed using Student\'s *t*-test for paired (BAY 11-7082 inhibitor, IL-6 and TNF ELISAs, proliferation assay) and unpaired observations (all other experiments) using GraphPad version 8. Statistical significance was set at *P* \< 0.05.

Results {#s3}
=======

HIV-1 Cap-RNA~58~ Induces Type I IFN Responses in Various Myeloid Cells
-----------------------------------------------------------------------

We used a synthetic RNA that mimics abortive HIV-1 RNAs: this synthetic HIV-1 Cap-RNA~58~ consists of the first 58 nucleotides common to all HIV-1 transcripts and contains a 5′cap while lacking a poly A tail ([Table S1](#SM4){ref-type="supplementary-material"}, [Figure 1A](#F1){ref-type="fig"}). We investigated whether HIV-1 Cap-RNA~58~ induced type I IFN responses in monocyte-derived DCs (DCs) by treating DCs with HIV-1 Cap-RNA~58~ complexed with transfection reagent lyovec (vehicle control) to facilitate cytoplasmic delivery ([@B27]). HIV-1 Cap-RNA~58~ induced strong *IFNB* transcription in DCs after 10 h of stimulation ([Figure 1B](#F1){ref-type="fig"}). Expression levels of interferon-stimulated gene (ISG) Myxovirus resistance protein 1 (MxA) transcripts were significantly induced by HIV-1 Cap-RNA~58~ in DCs as well when compared to untreated DCs ([Figure 1B](#F1){ref-type="fig"}). HIV-1 Cap-RNA~58~-induced type I IFN levels were compared to those observed with RLR agonist poly-I:C. After equalizing the amount of molecules of both HIV-1 Cap-RNA~58~ and poly-I:C ([Figure S1](#SM1){ref-type="supplementary-material"}), HIV-1 Cap-RNA~58~-induced type I IFN were significantly higher than poly-I:C-induced levels after 10 h of stimulation ([Figure 1B](#F1){ref-type="fig"}). We next investigated whether HIV-1 Cap-RNA~58~ activated responses in primary myeloid cells. Notably, treatment of CD14^+^ monocytes and monocyte-derived macrophages with HIV-1 Cap-RNA~58~ induced type I IFN responses 10 h after stimulation, whereas primary blood CD1c^+^ DCs showed type I IFN responses 8 h after stimulation. HIV-1 Cap-RNA~58~-induced type I IFN levels were higher than or comparable to poly-I:C-induced type I IFN responses ([Figure 1C](#F1){ref-type="fig"}). To assess the specificity of HIV-1 Cap-RNA~58~ for DDX3 and MAVS-dependent signaling, both DDX3 and MAVS were silenced in DCs by RNA interference (RNAi) ([Figure S2](#SM2){ref-type="supplementary-material"}). Silencing of either DDX3 or MAVS expression completely abrogated *IFNB* induced by HIV-1 Cap-RNA~58~, 2 h after stimulation ([Figure 1D](#F1){ref-type="fig"}). Both vehicle control and HIV-1 control RNA did not induce *IFNB* expression ([Figures 1A,D](#F1){ref-type="fig"}). These data indicate that HIV-1 Cap-RNA~58~ triggers type I IFN in a variety of myeloid cells via DDX3 and MAVS, and that the 5′cap is required for sensing by DDX3.

![HIV-1 Cap-RNA~58~ induces type I IFN responses in various myeloid immune cells. **(A)** Schematic sequence of HIV-1 control RNA and HIV-1 Cap-RNA~58~. **(B)** Monocyte-derived DCs, **(C)** CD14^+^ monocytes, monocyte-derived macrophages and CD1c^+^ DCs were stimulated with 1 nM HIV-1 Cap-RNA~58~ or poly-I:C complexed with lyovec (vehicle control), and both *IFNB* and *MXA* expression was measured by quantitative real-time PCR after 10 h (monocyte-derived DCs, CD14^+^ monocytes and monocyte-derived macrophages) or 8 h (CD1c^+^ DCs). Values were calculated relative to *GAPDH*. HIV-1 Cap-RNA~58~-induced responses were set as 1. **(D)** DCs were treated with vehicle control, 1 nM HIV-1 control RNA, and 1 nM HIV-1 Cap-RNA~58~, 72 h after silencing of DDX3 and MAVS. *IFNB* mRNA expression was measured after 2 h of stimulation by quantitative real-time PCR and mRNA expression was relative to *GAPDH*. HIV-1 Cap-RNA~58~-induced *IFNB* responses in siControl-treated DCs was set as 1. Data are representative of collated data of three **(B--D)** or four **(C**, monocyte-derived macrophages) donors (mean ± s.d.). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001, Student\'s *t*-test. NS, not significant.](fimmu-11-00008-g0001){#F1}

HIV-1 Cap-RNA~58~ Induces DC Maturation
---------------------------------------

To determine whether HIV-1 Cap-RNA~58~ induces adaptive immunity, we first examined the expression levels of costimulatory molecules CD80, CD83, and CD86 after stimulation with HIV-1 Cap-RNA~58~, by flow cytometry. HIV-1 Cap-RNA~58~ induced expression of CD80, CD83, and CD86 compared to unstimulated DCs, albeit to a lesser extent than LPS ([Figure 2A](#F2){ref-type="fig"}). HIV-1 Cap-RNA~58~ induced expression levels of activation marker HLA-DR to a similar extent as LPS, whereas the expression levels of costimulatory molecule CD40 remained unaffected in contrast to LPS stimulation ([Figure 2A](#F2){ref-type="fig"}). To investigate the role of IFNβ signaling in DC maturation, we neutralized IFNβ signaling by treatment with blocking IFNα/βR antibodies. CD86 induction by HIV-1 Cap-RNA~58~ was partially but significantly blocked by blocking IFNα/βR antibodies ([Figures 2B,C](#F2){ref-type="fig"}), suggesting that type I IFN induction increases CD86. Besides type I IFN-dependent CD86 expression, expression of costimulatory molecules can also be induced by the transcription factor NF-κB ([@B38], [@B39]). To test whether CD86 expression is also NF-κB dependent, we blocked NF-κB activation using BAY 11-7082, a small molecule inhibitor for IκBα, as release of the inhibitory protein IκBα from the NF-κB dimer within the cytoplasm is mandatory for NF-κB activation ([@B40]). BAY 11-7082 treatment significantly reduced HIV-1 Cap-RNA~58~-induced CD86 expression ([Figure 2C](#F2){ref-type="fig"}). Our results imply that HIV-1 Cap-RNA~58~ treatment leads to IFNβ- and NF-κB-dependent DC maturation.

![HIV-1 Cap-RNA~58~ induces DC maturation. **(A)** DCs were not treated or treated with 1 nM HIV-1 Cap-RNA~58~. DCs were fixed and expression levels of CD80, CD83, CD86, and CD40 (24 h after stimulation) and HLA-DR (48 h after stimulation) were measured by flow cytometry. **(B)** DCs were stimulated with 1 nM HIV-1 Cap-RNA~58~ in the presence or absence of blocking IFNα/βR antibodies or **(C)** with blocking IFNα/βR antibodies and BAY 11-7082 inhibitor. Geometric mean of the fluorescent intensity (GM of FI) of FITC was shown to indicate CD86 expression levels. Data are representative of at least three donors **(A--C)** from different experiments (mean ± s.d.). \**P* \< 0.05, Student\'s *t*-test.](fimmu-11-00008-g0002){#F2}

HIV-1 Cap-RNA~58~ Activates IRF3 and NF-κB p65
----------------------------------------------

We next investigated whether HIV-1 Cap-RNA~58~ activated transcription factors IRF3 and NF-κB, known to be involved in transcriptional regulation of a plethora of cytokine and other genes required for the orchestration of innate and adaptive immune responses by DCs ([@B14], [@B15], [@B19]). DCs were treated with HIV-1 Cap-RNA~58~ or LPS and translocation of p65, one of the primary active subunits within the dimeric NF-κB transcription factor family, was analyzed by immunofluorescence microscopy. Similarly, as was observed for IRF3, HIV-1 Cap-RNA~58~ induced p65 translocation to the nucleus, albeit to a lesser extent than observed for LPS-treated DCs ([Figures 3A,B](#F3){ref-type="fig"}). We next quantified nuclear translocation of p65 and IRF3 using a transcription factor binding assay using nuclear extracts from HIV-1 Cap-RNA~58~-activated DCs. HIV-1 Cap-RNA~58~ induced significant translocation of the p65 unit, 4 h after stimulation, in contrast to HIV-1 control RNA ([Figure 3C](#F3){ref-type="fig"}). Similarly, we quantified the nuclear translocation of IRF3, which was also detected in HIV-1 Cap-RNA~58~-activated but not HIV-1 control RNA-treated DCs ([Figure 3D](#F3){ref-type="fig"}). Thus, these data strongly indicate that HIV-1 Cap-RNA~58~ activates both IRF3 and NF-κB, implying that it can play a significant role in establishing innate and adaptive immune responses.

![HIV-1 Cap-RNA~58~ activates IRF3 and NF-κB p65. **(A,B)** DCs were not treated or treated with 1 nM HIV-1 Cap-RNA~58~ or LPS. After 4 h, cells were fixed, permeabilized and stained with Hoechst (to visualize the nucleus) and with anti-p65 or anti-IRF3 and secondary rabbit-Alexa-546-labeled antibodies and visualized using fluorescent microscopy, 100x magnification. **(C)** DCs were not treated or treated with vehicle control (lyovec), 1 nM HIV-1 control RNA, 1 nM HIV-1 Cap-RNA~58~ or LPS and nuclear extracts were obtained 4 h after stimulation. Twenty micrograms of nuclear extract was analyzed with a transAM assay to determine nuclear translocation of p65 **(D)** or IRF3, using OD450 nm. Data are representative of three donors of different experiments **(A)** or are collated data of six **(C)** or five **(D)** donors (mean ± s.d.). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, Student\'s *t*-test.](fimmu-11-00008-g0003){#F3}

HIV-1 Cap-RNA~58~ Induces Expression of Pro-Inflammatory Cytokines
------------------------------------------------------------------

We next assessed whether treatment of HIV-1 Cap-RNA~58~ triggered cytokine expression in DCs. HIV-1 Cap-RNA~58~ significantly induced expression of the pro-inflammatory cytokines IL-6 and TNF at both mRNA and protein level, compared to vehicle control and HIV-1 control RNA-treated DCs ([Figures 4A--C](#F4){ref-type="fig"}). Interestingly, HIV-1 Cap-RNA~58~ treatment of DCs did not induce mRNA expression of *IL1B, IL8, IL10*, and *IL23A* (data not shown). mRNA expression levels of *IL6* and *TNF* peaked at 10 h, while the ISG *IL27A*, which encodes IL-27p28, a subunit of IL-27, peaked at 8 h ([Figure 4A](#F4){ref-type="fig"}). At peak level, the expression levels of HIV-1 Cap-RNA~58~-induced *IL6, TNF, IL27A*, and *IL12A* mRNA were significantly increased compared to both vehicle control and HIV-1 control RNA ([Figure 4B](#F4){ref-type="fig"}). Whereas, *IL12A* transcription was induced upon treatment with HIV-1 Cap-RNA~58~, *IL12B* mRNA could not be detected ([Figure 4A](#F4){ref-type="fig"}). In line with the lack of expression of the *IL12B* subunit, no bioactive IL-12p70 protein could be detected in the supernatant of DCs after HIV-1 Cap-RNA~58~ treatment ([Figure 4C](#F4){ref-type="fig"}). Thus, HIV-1 Cap-RNA~58~ induces a specific cytokine program primarily directed at pro-inflammatory conditions.

![HIV-1 Cap-RNA~58~ induces expression of pro-inflammatory cytokines. **(A)** DCs were not treated or stimulated with 1 nM HIV-1 Cap-RNA~58~ and mRNA expression levels of *IL6, TNF, IL27A, IL12A*, and *IL12B* were measured every 2 h with quantitative real-time PCR, relative to *GAPDH*. HIV-1 Cap-RNA~58~-induced responses at 8 h were set as 1 for *IL6* and at 10 h for all other cytokines genes. **(B)** DCs were left untreated, treated with vehicle control or 1 nM HIV-1 control RNA or stimulated with 1 nM HIV-1 Cap-RNA~58~ and mRNA expression levels of *IL6, TNF, IL27A*, and *IL12A* were measured at peak level with quantitative real-time PCR, relative to *GAPDH*. HIV-1 Cap-RNA~58~-induced responses at 8 h were set as 1 for *IL6* and *TNF*, at 10 h for *IL27A* and at 24 h for *IL12A* gene expression. **(C)** DCs were left untreated, treated with vehicle control or 1 nM HIV-1 control RNA or stimulated with 1 nM HIV-1 Cap-RNA~58~ and supernatant was harvested after 24 or 48 h, to determine expression levels of IL-6 (48 h), TNF (24 h), and IL-12p70 (48 h) with ELISA. Data are representative of collated data of three donors **(A,B)** or representative of three donors of different experiments **(C)** (mean ± s.d.). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001, Student\'s *t*-test. NS, not significant.](fimmu-11-00008-g0004){#F4}

Different Viral HIV-1 RNAs Induce Similar Levels of Type I IFN and Pro-Inflammatory Cytokines
---------------------------------------------------------------------------------------------

To assess whether the ability of HIV-1 Cap-RNA~58~ to induce type I IFN and cytokine responses is due to the short RNA construct length, we examined the ability of a longer viral HIV-1 RNA in inducing immune activation. DCs treated with a 5′capped 630 nucleotides long RNA corresponding to the *Tat* transcript, which includes the same 1--58 sequence as the HIV-1 Cap-RNA~58~ at its start, but lacking a poly A tail (HIV-1 Cap-RNA~630~) induced antiviral responses comparable to those induced by HIV-1 Cap-RNA~58~. Similar to HIV-1 Cap-RNA~58~, HIV-1 Cap-RNA~630~ induced *IFNB* 2 h after stimulation reaching a peak level after 10 h ([Figure 5A](#F5){ref-type="fig"}). Similarly, HIV-1 Cap-RNA~630~ induced *MXA* and also another ISG *A3G* (encoding for APOBEC3G protein) transcription at similar levels as HIV-1 Cap-RNA~58~, peaking again at 10 h after stimulation ([Figure 5B](#F5){ref-type="fig"}). At peak levels, HIV-1 Cap-RNA~58~ significantly induced *IFNB, MXA*, and *A3G* gene expression compared to DCs treated with vehicle control or HIV-1 control RNA ([Figure 5C](#F5){ref-type="fig"}). We also assessed HIV-1 Cap-RNA~58~- and HIV-1 Cap-RNA~630~-induced *IL6, TNF, IL12A*, and *IL27A* transcription at time points that we had previously shown to have significantly enhanced expression after HIV-1 Cap-RNA~58~ treatment compared to untreated DCs and DCs treated with vehicle control and HIV-1 control RNA ([Figures 4A,B](#F4){ref-type="fig"}). At 6, 8 and 10 h after stimulation with the two HIV-1 Cap-RNAs, we observed that both constructs induced similar levels of *IL6, TNF, IL12A*, and *IL27A* mRNA ([Figure 5D](#F5){ref-type="fig"}). Although not significant, stimulation with HIV-1 Cap-RNA~630~ showed a trend toward increased *IL12A* expression compared to HIV-1 Cap-RNA~58~ after 6, 8, and 10 h of stimulation, and to a trend of increased *IL27A* expression after 10 h ([Figure 5D](#F5){ref-type="fig"}). These data suggest that the length of viral RNA constructs does not affect the strength of the type I IFN and pro-inflammatory cytokine responses as long as it contains a 5′cap and the first 58 nucleotides of the HIV-1 genome that form the TAR loop. Thus, synthetic HIV-1 RNAs induce antiviral innate immune responses independent of length.

![Different viral HIV-1 RNAs induce similar levels of type I IFN and pro-inflammatory cytokines. **(A)** DCs were not treated or treated with 1 nM HIV-1 Cap-RNA~58~ or 1 nM HIV-1 Cap-RNA~630~, mRNA was extracted every 2 h and analyzed for *IFNB* by quantitative real-time PCR and mRNA expression was analyzed relative to *GAPDH*. HIV-1 Cap-RNA~58~-induced responses at 10 h after stimulation were set as 1. Data point at 8 h after stimulation was also shown in [Figure 1A](#F1){ref-type="fig"}. **(B)** *MXA* or *APOBEC3G* mRNA expression was assessed similarly. Data point at 8 h after stimulation was also shown in [Figure 1B](#F1){ref-type="fig"}. **(C)** DCs were left untreated, treated with either vehicle control, 1 nM HIV-1 control RNA or 1 nM HIV-1 Cap-RNA~58~ and mRNA expression levels of *IFNB, MXA*, and *A3G* were measured at peak level with quantitative real-time PCR, relative to *GAPDH*. HIV-1 Cap-RNA~58~-induced responses at 10 h were set as 1. **(D)** *IL6, TNF, IL12A*, and *IL27A* mRNA expression was assessed similarly. Data are representative of collated data of three **(A,B,D)** or four **(C)** donors (mean ± s.d.). Statistical significance was determined between both HIV-1 RNA constructs and between unstimulated DCs and DCs treated with HIV-1 Cap-RNA~58~ or HIV-1 Cap-RNA~630~ **(D)**~.~ \**P* \< 0.05, \*\*\*\**P* \< 0.0001, Student\'s *t*-test. NS, not significant.](fimmu-11-00008-g0005){#F5}

HIV-1 Cap-RNA~58~-Activated DCs Induce T Cell Proliferation and Differentiation
-------------------------------------------------------------------------------

We next investigated the ability of HIV-1 Cap-RNA~58~-treated DCs to activate T cells. First we analyzed proliferation of CellTrace Violet-labeled peripheral blood cells (PBLs) induced by coculture for 5 days with DCs that were treated with vehicle control, HIV-1 control RNA, HIV-1 Cap-RNA~58~ or LPS. Flow cytometry analysis showed that HIV-1 Cap-RNA~58~-activated DCs enhanced proliferation of both CD4^+^ and CD8^+^ T cells compared to untreated DCs and DCs treated with vehicle control or HIV-1 control RNA ([Figures 6A,B](#F6){ref-type="fig"} and [Figure S3](#SM3){ref-type="supplementary-material"}). We next analyzed T~H~1 and T~H~2 differentiation after DC-naïve CD4^+^ T cell cocultures by intracellular IFNγ and IL-4 expression, respectively. HIV-1 Cap-RNA~58~-activated DCs showed significant skewing toward T~H~2 differentiation compared to the DCs treated with vehicle control or HIV-1 control RNA ([Figures 6C,D](#F6){ref-type="fig"}). As expected, positive controls LPS and PGE~2~ or LPS and IFNγ induced T~H~2 and T~H~1 responses, respectively, whereas LPS gave a mixed T~H~1/T~H~2 response ([Figures 6C,D](#F6){ref-type="fig"}). Thus, our data show that HIV-1 Cap-RNA~58~-treated DCs induce CD4^+^ and CD8^+^ T cell activation and skew adaptive immune response toward a T~H~2 phenotype.

![HIV-1 Cap-RNA~58~-treated DCs mediate T cell proliferation and differentiation. DCs were unstimulated or treated with 1 nM HIV-1 Cap-RNA~58~ or LPS for 48 h, cocultured with CellTrace Violet-labeled peripheral blood lymphocytes and harvested after 5 days. Proliferation was determined in **(A)** live CD3^+^ CD4^+^ cells and **(B)** CD3^+^ CD8^+^ T cells by flow cytometry. **(C,D)** DCs were treated with vehicle control, 1 nM HIV-1 control RNA, 1 nM HIV-1 Cap-RNA~58~, LPS, LPS + PGE~2~, or LPS + IFNγ for 48 h and cocultured with naïve T cells. After 11--13 days, cells were restimulated and intracellular expression levels of IFNγ (T~H~1) and IL-4 (T~H~2) were analyzed using flow cytometry. Number in plots indicate percentage of cells in the quadrant. Data are representative of collated data of three **(A,B)** or four **(D)** donors, or four donors **(C)** of different experiments (mean ± s.d.). \**P* \< 0.05, \*\**P* \< 0.01, Student\'s *t*-test. NS, not significant.](fimmu-11-00008-g0006){#F6}

HIV-1 Cap-RNA~58~ Inhibits HIV-1 Infection of DCs
-------------------------------------------------

To investigate whether treatment with HIV-1 Cap-RNA~58~ would block HIV-1 replication in DCs after infection, DCs were infected by R5-tropic HIV-1 NL4.3 BaL. After 24 h of ongoing HIV-1 infection the DCs were treated with HIV-1 Cap-RNA~58~ or LPS After 5 days, infection levels were assessed by measuring intracellular p24^+^ cells by flow cytometry. Although infection levels differed per donor, HIV-1 Cap-RNA~58~ decreased the percentage of HIV-1 p24^+^ DCs compared to HIV-1 control RNA-treated DCs in four different donors, albeit to a lesser extent than LPS ([Figures 7A,B](#F7){ref-type="fig"}). These results imply that HIV-1 Cap-RNA~58~ induces a functional antiviral response that limits HIV-1 infection.

![HIV-1 Cap-RNA~58~ reduces ongoing HIV-1 infection in DCs. **(A,B)** DCs were infected with NL4.3 BaL for 24 h, washed and incubated with 1 nM HIV-1 control RNA, 1 nM HIV-1 Cap-RNA~58~ or LPS. After 5 days, intracellular p24 levels were measured by flow cytometry. Data are representative of four donors **(A,B)**. (mean ± s.d.). \**P* \< 0.05, \*\*\**P* \< 0.001, Student\'s *t*-test. NS, not significant.](fimmu-11-00008-g0007){#F7}

Discussion {#s4}
==========

RNA helicase DDX3 is important for the transport of HIV-1 *Tat* mRNA as well as the formation of translation initiation complexes required for HIV-1 translation ([@B30]--[@B32]). Besides its role as a host factor for HIV-1, DDX3 also functions as a viral sensor ([@B27]). Here we investigated the potency and breadth of DDX3 ligand HIV-1 Cap-RNA~58~, a synthetic mimic of the naturally occurring abortive HIV-1 RNAs. We observed that HIV-1 Cap-RNA~58~ resulted in type I IFN responses in various myeloid cells in a DDX3- and MAVS-dependent manner. Our data further showed that HIV-1 Cap-RNA~58~ inhibited ongoing HIV-1 replication in DCs, most likely via the induced innate antiviral type I IFN responses. Moreover, HIV-1 Cap-RNA~58~ induced DC maturation and cytokine responses that led to adaptive T cell activation as well as differentiation. Thus, our data suggest that DDX3 is a PRR and shows that synthetic abortive HIV-1 RNA~58~ is immunostimulatory.

The potency of abortive HIV-1 RNA to exert an antiviral role in response to viral sensing by its natural ligand DDX3 is not well-understood. Therefore, we aimed to assess the role of abortive HIV-1 RNA in induction of innate and adaptive immune responses by using a synthetic mimic of abortive HIV-1 RNA (HIV-1 Cap-RNA~58~). Our data strongly suggest that synthetic HIV-1 Cap-RNA~58~ encapsulated in lyovec triggered DDX3 and MAVS-mediated IFNβ responses. It has been described that DDX3 has been found in complexes with RIG-I and MDA5 and might therefore induce IFNβ responses via a RIG-I or MDA5-MAVS-dependent way ([@B41]). We have previously shown in 293T cells treated with CRISPR-cas9 that depletion of RIG-I and MDA5 did not affect HIV-1 Cap-RNA~58~-induced type I IFN responses, indicating that the HIV-1 Cap-RNA~58~-induced type I IFN responses described here are generated in a DDX3-MAVS-TBK1-IRF3-dependent manner ([@B27]). Previous studies have shown that knockdown of DDX3 or the generation of phosphorylation-deficient DDX3 mutants in cell lines resulted in TBK1/IKKε-dependent decrease of the *IFNB* promotor activity, providing evidence that DDX3 is involved in the induction of *IFNB* transcription ([@B24], [@B25]). In line with the previous reported data obtained in cell lines, we have shown that DDX3 induces type I IFN responses in monocyte-derived DCs as well as primary monocytes, monocyte-derived macrophages and primary human CD1c^+^ DCs.

Synthetic abortive HIV-1 Cap-RNA~58~ contains a 5′cap and a secondary TAR loop structure and is a ligand for DDX3, which leads to the induction of type I IFN responses ([@B27]). The HIV-1 Cap-RNA~58~-induced type I IFN responses were similar if not stronger than those observed by poly-I:C, which triggers RIG-I and MDA5. RIG-I and MDA5 distinguish the recognition of their viral ligands based on RNA structure and length. RIG-I recognizes ssRNAs and short dsRNAs, whereas MDA5 recognizes longer dsRNAs ([@B42]). Soto-Rifo et al. have described that DDX3 recognizes viral RNA constructs due to the presence of a 5′cap in close proximity to a complex secondary structure ([@B30]). Whether DDX3 is able to distinguish between different viral RNA lengths and adapts subsequent immune activation is unknown. Here we aimed to assess whether differences in HIV-1 Cap-RNA construct length would lead to varying immune activation levels. We observed that the length of the synthetic viral ligand did not affect the strength of the antiviral type I IFN responses as both HIV-1 Cap-RNA~58~ and HIV-1 Cap-RNA~630~ induced similar levels of *IFNB* and *ISG* mRNA expression. Similar levels of pro-inflammatory cytokines were also observed. Whereas, HIV-1 Cap-TAR~58~ induced type I IFN responses, HIV-1 control RNA did not result in *IFNB* mRNA expression, indicating that the 5′cap is required for recognition by DDX3 and subsequent induction of antiviral responses. Thus, HIV-1 Cap-RNA~58~ induces potent type I IFN in DCs via DDX3 and MAVS-dependent signaling, due to the presence of a 5′cap and complex secondary TAR loop structure.

Besides type I IFN responses, HIV-1 Cap-RNA~58~ resulted in increased upregulation of costimulatory molecules CD80, CD83, and CD86. Furthermore, HIV-1 Cap-RNA~58~ enhanced expression of HLA-DR but not CD40. Our data further indicate that DC maturation is dependent on both type I IFN and NF-κB activation. It remains to be established whether the effect of NF-κB is mediated via IFNβ or that other cytokines activated by NF-κB further affect DC maturation in combination with IFNβ. It has previously been described for various cell lines that DDX3 expression knockdown results in decreased NF-κB p65 phosphorylation and cytokine responses suggesting that DDX3 plays a stimulatory role in NF-κB signaling ([@B43]). In addition, Ku et al. ([@B44]) described that in THP-1-differentiated macrophages DDX3 is important for TNF, IL-1β, CCL2, and CCL5 expression as knockdown of DDX3 expression impaired cytokine and chemokine expression in response to LPS and poly-I:C stimulations. Besides affecting pro-inflammatory cytokine responses, DDX3 knockdown also led to impaired migration and phagocytic capacities of THP-1-differentiated macrophages ([@B44]). Although it is unclear whether these functions can be induced by viral ligands, these data potentially imply that DDX3 could be involved in orchestrating various important functions in DCs. Our data underscore the importance of DDX3 as a viral sensor important for the induction of antiviral immunity.

We observed that HIV-1 Cap-RNA~58~ induced expression of pro-inflammatory cytokines IL-6 and TNF, which are important for both innate and adaptive immune responses. Furthermore, HIV-1 Cap-RNA~58~ induced *IL12A* but not *IL12B* mRNA expression which resulted in the absence of heterodimeric IL-12p70 protein that is crucial for the induction of T~H~1 differentiation. The observed lack of IL-12p70 upon stimulation with HIV-1 Cap-RNA~58~ might explain skewing of T helper differentiation toward a T~H~2 phenotype by HIV-1 Cap-RNA~58~-treated DCs. Furthermore, we observed HIV-1 Cap-RNA~58~-dependent induction of *IL27A*, encoding for one of the subunits of heterodimeric IL-27 protein, important in the induction of follicular T helper (T~FH~) cells ([@B45]). Both T~H~2 and T~FH~ cells are important for the induction of antibody responses against invading pathogens including viruses ([@B46]). T~FH~ cells are important for the formation and maintenance of germinal centers (GCs) and subsequent differentiation of B cells in GCs ([@B46]). Once a B cell exits the GC, T~H~2-induced IL-4 production can direct class switching from immunoglobulin G (IgG) to IgE antibodies ([@B47], [@B48]). Recent studies show that T~FH~ responses are required to induce broadly neutralizing antibodies against HIV-1 ([@B49]--[@B51]). Although it is unclear yet whether HIV-1 Cap-RNA~58~ induces a T~FH~ phenotype, the cytokine responses and T~H~2 differentiation suggest that HIV-1 Cap-RNA~58~ can be useful in vaccines to induce neutralizing antibodies against HIV-1 or other viruses.

Microbial LPS is increased in serum of HIV-1 infected individuals due to intestinal damage upon CD4^+^ T cell depletion. LPS as a potent immunostimulatory compound could be involved in inflammatory responses during chronic phase of infection ([@B52], [@B53]). Interestingly, several studies suggest that HIV-1 replication in latent infected cells produces short abortive RNAs such as the DDX3 ligand HIV-1 Cap-RNA~58~ ([@B54], [@B55]). Our study suggest that these abortive RNAs can induce inflammatory responses. Thus, besides increased translocation of microbial LPS, the production of HIV-1 Cap-RNA~58~ in latent infected cells can also contribute to immune activation observed in HIV-1 infected individuals during chronic phase of infection.

In conclusion, DDX3 is a highly versatile protein involved in a multitude of cellular processes. During HIV-1 infection, the dual role of DDX3 in exerting both proviral and antiviral capacities provides insight in its complexity and to the various roles DDX3 might play in establishing immunity. Here we have identified the antiviral role of DDX3 upon sensing of a viral-derived RNA and how its ligands can be used as adjuvants. Our data strongly indicate that HIV-1 Cap-RNA~58~ induces potent antiviral innate and adaptive immune responses in human DCs or directed by human DCs. Our data shows that DDX3 is a pattern recognition receptor and its synthetic ligands can be used as adjuvants to induce potent immune responses.
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